SERD Therapeutics Market worth $ 5.75 Billion by 2030 - Exclusive Report by InsightAce Analytic

07 Jun 2022
www.prnewswire.com
Generic DrugOligonucleotideCell TherapyAcquisitionCollaborate
JERSEY CITY, N.J., June 7, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on
"Global SERD Therapeutics Market (Products (Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, and Other Generics), Therapy (First-Line Treatment, Second-Line Treatment))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030"
According to the latest research by InsightAce Analytic, the global SERD therapeutics market size valued at US$ 1.33 billion, and it is expected to reach US$ 5.75 billion in 2030, recording a promising CAGR of 17.9% during the period of 2020-2030.
Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD and full receptor antagonist are essential treatment options for HR-positive breast cancer. Tamoxifen, a particular estrogen receptor modulator (SERM) with receptor agonist and antagonist action, and aromatase inhibitors, which prevent estrogen production, but cause acquired resistance, are examples of endocrine medicines. Fulvestrant, the only SERD currently licensed, has weak drug-like characteristics. The development of oral SERDs with optimal target occupancy and potency and enhanced clinical performance has been a primary emphasis for improving disease management. The increasing investments by key players in the development of promising breast cancer therapies are anticipated to fuel the SERD therapeutics market growth over the forecast period.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1246
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, rising number of clinical trials. Furthermore, the fast adoption of advanced medical technologies, population growth, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market. However, the high price of devices, complex procedures, and resistance to endocrine therapy is restraining the development of this market. Moreover, the COVID-19 pandemic has both positively and negatively impacted the SERD therapeutics market due to the lockdown situations.
At the regional level, the North American region is the major revenue holder of this market due to rising awareness about SERD therapies, increasing government investments in the research and development of therapies for the treatment of various cancer diseases, and the rising prevalence of breast cancer. On the other hand, the Europe region will also dominate the market during the forecast period due to the advancements in the biopharmaceutical field, stringent regulations, and the increasing prevalence of chronic diseases. The Asia-Pacific market is projected to show significant growth in the future due to the growing SERD therapeutic industries and fast adaption of new technologies.
Enquiry Before Buy:
https://www.insightaceanalytic.com/enquiry-before-buying/1246
Leading manufacturers in this field are focusing on novel SERD therapy innovations, making new partnerships, collaborations and agreements, growing awareness about SERD therapies, and increasing research investments for developing advanced technologies. These strategies will propel their growth opportunities in the market. In 2020, QLHC announced an evaluation of Sanofi's SAR439859, an oral estrogen receptor degrader (SERD), in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. AstraZeneca moved its next-generation oral SERD AZD9833 into phase 1 in 2018. While work on AZD9496 stalled after a few early clinical trials, AstraZeneca has quickly expanded and advanced the development of AZD9833. Late last month, AstraZeneca began enrolling patients in the phase 3 clinical trial of AZD9833.
Recent Key Developments:
In June 2021, Eli Lilly and Company presented new results for the exploratory use of Verzenio® (abemaciclib) in high-risk early breast cancer, as well as for its oral selective oestrogen receptor degrader (SERD) LY3484356 (ASCO). Lilly is releasing an exploratory analysis from the positive Phase 3 monarch study testing Verzenio, a CDK4/6 inhibitorCDK4/6 inhibitor, in a subset of patients with HR+, HER2-, high-risk early breast cancer (EBC)HER2-, high-risk early breast cancer (EBC) who had had neoadjuvant chemotherapy.
In Sept 2020, InventisBio recently announced the conclusion of a $147 million series D fundraising, which included several of the world's leading biopharmaceutical and healthcare venture capital firms. InventisBio currently has three medicinal compounds in various stages of clinical development, and one new product has recently begun a worldwide phase I clinical trial. D-0502 showed remarkable anti-tumour effectiveness in phase 1 research, with superior absorption and an acceptable safety profile when compared to other oral SERDs in clinical development throughout the world.
In Sept 2019, Preliminary data from a Phase 1/2a dose-escalation trial of G1T48, an oral selective oestrogen receptor degrader (SERD), in patients with oestrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer were released by G1 Therapeutics, Inc. G1T48 was well tolerated in the study and showed anti-tumour effectiveness in patients who had been substantially pre-treated. The results of this trial support the future development of G1T48 in both first line and adjuvant settings, and a first-line Phase 3 pivotal trial is expected to begin in 2020.
Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Other Generics
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Therapy
Second-Line Treatment
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Region
North America
Europe
Latin America
Middle East & Africa
North America SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030
U.S.
Canada
Europe SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030
India
China
Japan
South Korea
Australia & New Zealand
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Brazil
Mexico
Rest of Latin America
Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030
GCC Countries
South Africa
Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for global SERD therapeutics market
To receive industry overview and future trends of global SERD therapeutics market
To analyse the SERD therapeutics market drivers and challenges
To get information on SERD therapeutics market size value (US$ Mn) forecast till 2030
Major Investments, Mergers & Acquisition in global SERD therapeutics market industry
For Customization @ https://www.insightaceanalytic.com/customisation/1246
Other Related Reports Published by InsightAce Analytic:
Global RNA-based Therapeutics Market
Global Stem Cell Exosome Therapeutic Market
Global Antisense Oligonucleotide Therapeutics Market
Global Oncolytic Virus Therapy Market
Global Immuno-Oncology Cell Therapy Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
SOURCE InsightAce Analytic Pvt. Ltd.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.